title: Frontline treatment of multiple myeloma.
abstract: The treatment of myeloma has been revolutionized by the availability of new drugs. Combination therapy followed by stem cell transplant holds the promise of ultimately curing a fraction of patients. Objective responses are the norm for induction therapy and up to  50% of patients achieve a complete remission. Ongoing clinical trials continue to address the role of long term maintenance therapy. Understanding the proper management of these agents is paramount to providing patients disease control and yet minimizing side effects from treatment.
authors.affiliation: Mayo Clinic Cancer Center, Center for Individualized Medicine, 13400 East Shea Boulevard, Collaborative Research Building, 1-105 Scottsdale, AZ 85259-5494, USA. fonseca.rafael@mayo.edu
authors.forename: Rafael
authors.initials: R
authors.lastname: Fonseca
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001897:Boronic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D000069286:Bortezomib; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D046988:Proteasome Endopeptidase Complex / Q000008:administration & dosage; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D061988:Proteasome Inhibitors; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D046988:Proteasome Endopeptidase Complex; D000077269:Lenalidomide